Type 1 Diabetes Research could be approaching a significant turning point in Canada, and an Ajax advocate says increased federal investment could help Canadian scientists turn promising discoveries into treatments that reach patients.
Kat Spargalo, an Ajax resident who was diagnosed with Type 1 diabetes at four years old, is among advocates calling on the federal government to invest $62 million over five years to establish the Breakthrough T1D Network in Canada.
The proposed federal contribution would support a larger $100-million initiative. According to Spargalo, another $25 million would come from Breakthrough T1D, while research institutions, industry and other partners would contribute approximately $13 million.
Ajax advocate pushes for federal investment
Spargalo recently returned from the T1D on the Hill conference in Ottawa, where she joined approximately 30 advocates calling for stronger federal support for diabetes research.
For Spargalo, the issue is deeply connected to decades of managing the disease.
While technology has significantly improved diabetes management, she stressed that better management is different from finding a cure. People with Type 1 diabetes must continually monitor and manage their condition.
She believes Canada has an opportunity to build on its historic role in diabetes research by creating a coordinated system that connects researchers, clinicians, hospitals and industry.
Rather than establishing another standalone research facility, the proposed network would connect existing Canadian expertise and help promising discoveries move more efficiently into clinical trials and eventually patient care.
Canadian researchers pursuing new therapies
Supporters believe Type 1 Diabetes Research has reached an important stage, particularly as scientists investigate cell-based therapies intended to restore insulin production.
Spargalo said developments that once seemed decades away are now entering or approaching clinical trials.
She argues that greater coordination could also help Canada retain researchers, clinical trials, intellectual property and investment rather than losing opportunities to countries moving more quickly in regenerative medicine.
Spargalo’s connection to Durham Region’s diabetes-care community also includes the Charles H. Best Diabetes Centre in Whitby, where she said she eventually found knowledgeable care after searching for appropriate support elsewhere in Ontario.
Potential benefits beyond diabetes
Advocates say investment in the proposed network could have implications beyond Type 1 diabetes.
The research infrastructure, expertise and collaborative systems developed through the initiative could potentially contribute to work involving regenerative medicine, organ repair, rare diseases and cancer.
Supporters also argue that accelerating effective treatments could reduce the long-term financial burden associated with chronic disease.
According to figures cited by Spargalo, accelerating curative therapies for Type 1 diabetes by five years could potentially reduce health-care costs by billions of dollars.
The proposed initiative is also projected by its supporters to generate significant economic activity and create more than 120 highly skilled jobs during its first five years.
Advocacy campaign continues
Spargalo is encouraging Canadians to raise awareness about the proposed Type 1 Diabetes Research investment and contact elected representatives about federal support.
She emphasized that advocacy does not need to be limited to people living with the disease. Families and friends also experience the challenges associated with managing a condition that requires constant attention.
For Spargalo, Canada’s existing expertise makes the current moment particularly important.
Her message is that Canada already possesses researchers and scientific knowledge capable of advancing promising treatments, but needs investment and national coordination to move discoveries toward patients more effectively.
Advocates hope the proposed Breakthrough T1D Network can provide that framework while strengthening Canada’s broader capacity in regenerative medicine.
With more than 300,000 Canadians identified in the campaign as living with Type 1 diabetes, supporters say accelerating Type 1 Diabetes Research could have significant implications for patients, Canada’s health-care system and the country’s future role in medical innovation.
